For those involved in outsourcing, the new FDA draft guidance regarding FDA Form 483 observations reshapes the accountability framework. The public comment period ends May 8.
- SUS Interchangeability Assessment And Qualification Best Practices
- 5 QMS Blind Spots You Should Know About
- New MIT Consortium Links Innovation With Real-World Biomanufacturing
- The Hidden Engineering Behind Successful Upstream Bioprocessing
- A Practical Look At Modern Downstream Processing For Biologics
- Process Engineering's Key Role In Sterile Injectable Facility Design
- What To Know About — And How To Apply For — FDA's PreCheck Pilot
GUEST COLUMNISTS
-
SUS Interchangeability Assessment And Qualification Best Practices
Establishing a robust single-use systems (SUS) interchangeability program can be a pivotal feature of a supply chain resiliency initiative.
-
5 QMS Blind Spots You Should Know About
Companies often underestimate the complexity of standing up an eQMS. These are five of the most common issues that lead to regulatory and GMP exposure risk.
-
New MIT Consortium Links Innovation With Real-World Biomanufacturing
In one area, the Initiative for New Manufacturing is exploring whether microfactories, championed by the EV industry, can help biopharma iterate facility design faster.
-
The Hidden Engineering Behind Successful Upstream Bioprocessing
In upstream biopharmaceutical production, manufacturing is inseparable from biology, engineering, contamination control, and quality science.
-
A Practical Look At Modern Downstream Processing For Biologics
Part 2 in a series about current bioprocessing practices explores the latest in separation, purification, sterile filtration and aseptic filling.
-
Process Engineering's Key Role In Sterile Injectable Facility Design
Quality requirements for parenteral drugs complicate facility design like few other regulated products. If you're developing injectables, be aware of these key issues.
-
What To Know About — And How To Apply For — FDA's PreCheck Pilot
FDA has now provided specific eligibility and selection criteria for the PreCheck Pilot Program and a timeline for next steps.
BIOSIMILAR WHITE PAPERS
-
Regulatory Considerations For Excipients Used In Lipid Nanoparticles
Review the regulatory classification of LNPs, liposomes, and novel excipients as well as specific requirements outlined in regulatory guidance documents and strategies to navigate emerging challenges.
-
The Role Of Extractables Data In The Adoption Of Single-Use Systems8/29/2024
Explore guidance for evaluating single-use systems for extractables and leachables, and learn how supplier-provided single-use system extractables data can save both time and resources.
-
Achieve Higher Targeted Concentrations9/30/2025
Single-pass TFF streamlines downstream processing by reducing footprint, shear exposure, and hold-up volumes. Learn how this approach is advancing efficiency across therapeutic and vaccine production.
-
Business Continuity Management: The Benzonase® Endonuclease Success Story8/21/2024
Business continuity management is a key success contributor to the pharma industry. Explore best practices for a robust supply chain and how they can translate into success stories.
-
Considerations For Developing The Recirculation/Perfusion Process6/6/2024
Learn about the recirculation and perfusion processes made possible by single-use, fixed-bed bioreactors designed for scaling up adherent cell culture processes.
-
Performance Characteristics Of The Mobius® ADC Reactor For Conjugation10/22/2024
Explore results from a series of studies evaluating the mixing performance of an innovative ADC reactor during the conjugation step utilizing a model fluid.
BIOSIMILAR APP NOTES & CASE STUDIES
- Get Full Control Of Your T Cell Isolation
- Improving Bioprocess Monitoring And Control With Multivariate Data Analysis
- Enhanced Flow Kit Performance With Leak And PUPSIT Testing
- Packing MabSelect™ And MabSelect SuRe™ Resins Using Verified Methods
- Automation And Digital Solutions Can Help You Reach Your mRNA Manufacturing And Sustainability Goals
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- 3PBIOVIAN And INC Partner To Expand Access To Oncology Treatments In Colombia Through Biosimilar Development
- Celltrion Set To Benefit From Global Biosimilar Regulatory Streamlining, Driving Economies Of Scale From Development To Manufacturing And Direct Sales
- Celltrion Launches Remsima IV Liquid Formulation In Europe, Securing New Competitiveness To Lead The Global infliximab Market
- AAM And Biosimilars Council Laud FDA Plan To Streamline Biosimilar Medicines Development And Lower Costs For Patients
- Gannet BioChem Files Type II Drug Master File For mPEG Propionaldehyde 20K To Support Pegfilgrastim Biosimilars
- FDA Issues Landmark Biosimilar Guidance Incorporating Regulatory Reforms Advised By Professor Niazi: Further Cutting Development Costs By Up to 50%
- mAbxience Selects Genedata Bioprocess To Automate End-To-End CDMO Workflows
- Sandoz Creates New Global Biosimilar Development, Manufacturing And Supply Unit, Appoints Industry Veteran Armin Metzger To Lead Next Phase Of Growth
NEWSLETTER ARCHIVE
- 03.05.26 -- Phase-Appropriate Control Lessons For mAb/ADC Manufacturers
- 02.26.26 -- New ISPE Framework Targets Uncertainty In Pharma's AI Deployment
- 02.19.26 -- Why Use Total Organic Carbon Analysis For Cleaning Validation?
- 02.12.26 -- Building Enterprise Resilience From QRM Signals
- 01.29.26 -- The Latest In Upstream HCP Mitigation